Skip to content 
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. more
| Time Frame | CTNM | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -0.26% | 0.72% | -1.31% |
| 1-Month Return | 28.44% | 1.27% | 0.78% |
| 3-Month Return | 32.23% | 3.13% | 3.46% |
| 6-Month Return | 87.9% | 15.81% | 6.19% |
| 1-Year Return | 106.79% | 8.89% | 11.68% |
| 3-Year Return | -4.87% | 20.79% | 71.21% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | 50.00M | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Cost of Revenue | - | 329.00K | 195.00K | 258.00K | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.27,"profit":true},{"date":"2024-12-31","value":78.42,"profit":true}] | |
| Gross Profit | - | (329.00K) | 50.00M | (258.00K) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-0.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-0.52,"profit":false}] | |
| Gross Margin | - | - | 100.00% | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Operating Expenses | 28.65M | 22.39M | 66.08M | 50.64M | [{"date":"2021-12-31","value":43.35,"profit":true},{"date":"2022-12-31","value":33.89,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":76.63,"profit":true}] | |
| Operating Income | (28.65M) | (22.72M) | (16.08M) | (50.89M) | [{"date":"2021-12-31","value":-2864700000,"profit":false},{"date":"2022-12-31","value":-2272000000,"profit":false},{"date":"2023-12-31","value":-1607700000,"profit":false},{"date":"2024-12-31","value":-5089400000,"profit":false}] | |
| Total Non-Operating Income/Expense | (609.00K) | (1.16M) | 43.65M | 17.54M | [{"date":"2021-12-31","value":-1.4,"profit":false},{"date":"2022-12-31","value":-2.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":40.19,"profit":true}] | |
| Pre-Tax Income | (29.00M) | (24.25M) | 23.17M | (42.26M) | [{"date":"2021-12-31","value":-125.17,"profit":false},{"date":"2022-12-31","value":-104.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-182.38,"profit":false}] | |
| Income Taxes | 241.00K | - | 450.00K | - | [{"date":"2021-12-31","value":53.56,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Income After Taxes | (29.24M) | - | 22.72M | - | [{"date":"2021-12-31","value":-128.71,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (29.00M) | (24.25M) | 22.72M | (42.26M) | [{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-185.99,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |
| Net Income | (29.00M) | (24.25M) | 22.72M | (42.26M) | [{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-185.99,"profit":false}] | |
| EPS (Diluted) | - | - | (1.44) | (4.90) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-144,"profit":false},{"date":"2024-12-31","value":-490,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| CTNM | |
|---|---|
| Cash Ratio | 28.68 |
| Current Ratio | 29.07 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CTNM | |
|---|---|
| ROA (LTM) | -20.89% |
| ROE (LTM) | -30.40% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CTNM | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CTNM | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 11.15 |
| P/B | 2.92 |
| Price/FCF | NM |
| EV/R | 8.25 |
| EV/Ebitda | 20.76 |
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) share price today is $15.22
Yes, Indians can buy shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) on Vested. To buy
Yes, you can purchase fractional shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via the Vested app. You can start investing in Contineum Therapeutics, Inc. Class A Common Stock (CTNM) with a minimum investment of $1.
You can invest in shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via Vested in three simple steps:
The 52-week high price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $16.01. The 52-week low price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $3.35.
The price-to-earnings (P/E) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is
The price-to-book (P/B) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 2.92
The dividend yield of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 0.00%
The market capitalization of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $536.62M
The stock symbol (or ticker) of Contineum Therapeutics, Inc. Class A Common Stock is CTNM
Consider the share price of Contineum Therapeutics, Inc. Class A Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Contineum Therapeutics, Inc. Class A Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Contineum Therapeutics, Inc. Class A Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Contineum Therapeutics, Inc. Class A Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Contineum Therapeutics, Inc. Class A Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Contineum Therapeutics, Inc. Class A Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
